Versanis Bio Overview
- Year Founded
-
2020
- Status
-
Acquired/Merged
- Employees
-
21
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$1.93B
Versanis Bio General Information
Description
Developer of medicines designed to address medical conditions prevalent in older adults. The company offers treatment that induces loss of fat mass without loss of lean mass and improves cardiometabolic parameters, enabling overweight and obese adults to maintain healthy body composition.
Contact Information
Website
www.versanisbio.comCorporate Office
- 1111 Broadway
- Suite 1300
- Oakland, CA 94607
- United States
Corporate Office
- 1111 Broadway
- Suite 1300
- Oakland, CA 94607
- United States
Versanis Bio Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Merger/Acquisition | 14-Aug-2023 | $1.93B | Completed | Generating Revenue | ||
| 1. Early Stage VC (Series A) | 31-Aug-2021 | Completed | Clinical Trials - Phase 2 |
Versanis Bio Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A |
Versanis Bio Comparisons
Industry
Financing
Details
Versanis Bio Competitors (1)
One of Versanis Bio’s competitors is ERX Pharmaceuticals, a Corporation company based in Cambridge, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| ERX Pharmaceuticals | Corporation | Cambridge, MA |
Versanis Bio Patents
Versanis Bio Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2025227988-A1 | Actrii antibodies with extended half life | Pending | 28-Feb-2024 | ||
| WO-2025183966-A1 | Actrii antibodies with extended half life | Pending | 28-Feb-2024 | ||
| JP-2025529933-A | Actrii antibody fixed unit dose treatment | Pending | 26-Aug-2022 | ||
| AU-2023329487-A1 | Actrii antibody fixed unit dose treatments | Pending | 26-Aug-2022 | ||
| EP-4577301-A1 | Actrii antibody fixed unit dose treatments | Pending | 26-Aug-2022 | C07K16/2863 |
Versanis Bio Signals
Versanis Bio Former Investors (5)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Aditum Bio | Venture Capital | Minority | ||
| Atlas Venture | Venture Capital | Minority | ||
| Forbion | Venture Capital | Minority | ||
| Medicxi Ventures (UK) | Venture Capital | Minority | ||
| TCG Crossover Management | Venture Capital | Minority |
Versanis Bio FAQs
-
When was Versanis Bio founded?
Versanis Bio was founded in 2020.
-
Where is Versanis Bio headquartered?
Versanis Bio is headquartered in Oakland, CA.
-
What is the size of Versanis Bio?
Versanis Bio has 21 total employees.
-
What industry is Versanis Bio in?
Versanis Bio’s primary industry is Drug Discovery.
-
Is Versanis Bio a private or public company?
Versanis Bio is a Private company.
-
What is the current valuation of Versanis Bio?
The current valuation of Versanis Bio is .
-
What is Versanis Bio’s current revenue?
The current revenue for Versanis Bio is .
-
How much funding has Versanis Bio raised over time?
Versanis Bio has raised $70M.
-
Who are Versanis Bio’s investors?
Aditum Bio, Atlas Venture, Forbion, Medicxi Ventures (UK), and TCG Crossover Management have invested in Versanis Bio.
-
Who are Versanis Bio’s competitors?
ERX Pharmaceuticals is a competitor of Versanis Bio.
-
When was Versanis Bio acquired?
Versanis Bio was acquired on 14-Aug-2023.
-
Who acquired Versanis Bio?
Versanis Bio was acquired by Lilly USA.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process